Teva Pharmaceutical (TEVA) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Q2 2026
EPS
$0.02
est $0.11
-81.5%
Revenue
$4.14B
est $4.03B
+2.8%
A $726 million charge from the Emalex acquisition wiped out earnings, but Teva's branded drug pivot is firing: innovative brands crossed $1 billion in quarterly revenue for the first time and the company raised its full-year outlook, signaling confidence that the transformation will sustain.